1. Scrip
  2. >>Business

New CNS-Focused Biotech Cerevance Launches With Takeda Backing

 
• By Lucie Ellis-Taitt

Takeda invests in CNS startup, Cerevance, as part of its externalized R&D strategy.

Cerevance – a company focused on novel therapeutics for neurological and psychiatric disorders – has launched with operations in the US and the UK, after securing investment from Takeda Pharmaceutical Co. Ltd. and Lightstone Ventures. Takeda has granted the startup its recently shuttered Cambridge, UK laboratory site to progress several preclinical and early stage assets targeting central nervous system (CNS) indications.

Cerevance, which is based on technology created in the Howard Hughes Medical Institute laboratory of Dr Nathaniel Heintz at the Rockefeller University, has already secured $36m in funding – including a $21

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.